Clinical Trial Details

< Previous Trial     Next Trial >
Study ID CDR0000066964
Investigator
William D. Figg,   National Cancer Institute (NCI)
Title Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
Conditions Stage IV Prostate Cancer
Bone Metastases
Adenocarcinoma of the Prostate
Recurrent Prostate Cancer
Interventions Drug: alendronate sodium
Drug: ketoconazole
Phase Phase 2
Purpose RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium. PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Both
Accepts Healthy Volunteers: 
Study Location
Contact

Information objtained from ClinicalTrials.gov, on 9/19/2014. For additional information about this and other clinical trials, visit http://clinicaltrials.gov.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00019695


Back to Search Results